DK1242118T3 - Fremgangsmåder til behandling af iskæmisk eller hæmorrhagisk beskadigelse af centralnervesystemet under anvendelse af anti-alfa4-integrin-antagonister - Google Patents
Fremgangsmåder til behandling af iskæmisk eller hæmorrhagisk beskadigelse af centralnervesystemet under anvendelse af anti-alfa4-integrin-antagonisterInfo
- Publication number
- DK1242118T3 DK1242118T3 DK00984395T DK00984395T DK1242118T3 DK 1242118 T3 DK1242118 T3 DK 1242118T3 DK 00984395 T DK00984395 T DK 00984395T DK 00984395 T DK00984395 T DK 00984395T DK 1242118 T3 DK1242118 T3 DK 1242118T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- nervous system
- central nervous
- integrin antagonists
- treating ischemic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17126599P | 1999-12-16 | 1999-12-16 | |
PCT/US2000/033942 WO2001043774A1 (en) | 1999-12-16 | 2000-12-14 | Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1242118T3 true DK1242118T3 (da) | 2010-01-11 |
Family
ID=22623149
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00984395T DK1242118T3 (da) | 1999-12-16 | 2000-12-14 | Fremgangsmåder til behandling af iskæmisk eller hæmorrhagisk beskadigelse af centralnervesystemet under anvendelse af anti-alfa4-integrin-antagonister |
DK09012818.2T DK2140881T3 (da) | 1999-12-16 | 2000-12-14 | Fremgangsmåder til behandling af iskæmisk eller hæmoragisk læsion i centralnervesystemet ved anvendelse af anti-alpha-4-integrin-antagonister |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09012818.2T DK2140881T3 (da) | 1999-12-16 | 2000-12-14 | Fremgangsmåder til behandling af iskæmisk eller hæmoragisk læsion i centralnervesystemet ved anvendelse af anti-alpha-4-integrin-antagonister |
Country Status (11)
Country | Link |
---|---|
US (1) | US20020197233A1 (ja) |
EP (3) | EP2332578A1 (ja) |
JP (3) | JP2003517023A (ja) |
AT (1) | ATE447969T1 (ja) |
AU (1) | AU783110B2 (ja) |
CA (1) | CA2394431C (ja) |
DE (1) | DE60043308D1 (ja) |
DK (2) | DK1242118T3 (ja) |
ES (2) | ES2415708T3 (ja) |
NZ (1) | NZ519447A (ja) |
WO (1) | WO2001043774A1 (ja) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2106864C1 (ru) * | 1995-10-23 | 1998-03-20 | Николай Серафимович Зефиров | Средство для лечения болезни альцгеймера |
PT1214091E (pt) * | 1999-09-14 | 2006-09-29 | Imperial College | Terapias para a insuficiencia renal cronica utilizando um ou mais antaginistas de integrina |
US6960597B2 (en) * | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
FR2827174B1 (fr) * | 2001-07-13 | 2004-08-06 | Soc Extraction Principes Actif | Utilisation de peptides pour augmenter l'adhesion cellulaire |
CA2514125A1 (en) | 2003-01-24 | 2004-08-12 | Elan Pharmaceuticals, Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
WO2004100882A2 (en) * | 2003-05-06 | 2004-11-25 | Syntonix Pharmaceuticals, Inc. | Inhibition of drug binding to serum albumin |
US20050176755A1 (en) * | 2003-10-31 | 2005-08-11 | Dyatkin Alexey B. | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists |
US20070179174A1 (en) * | 2003-12-08 | 2007-08-02 | Bachurin Sergei O | Methods and compositions for slowing aging |
RU2283108C2 (ru) * | 2003-12-08 | 2006-09-10 | Сергей Олегович Бачурин | ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
NZ584288A (en) | 2004-02-06 | 2011-10-28 | Elan Pharm Inc | Methods and compositions for treating tumors and metastatic disease |
BRPI0506676A (pt) * | 2004-02-10 | 2007-05-15 | Janssen Phamaceutica N V | piridazinona uréias como antagonistas de integrinas alfa4 |
US8518021B2 (en) * | 2004-05-27 | 2013-08-27 | Baxter International Inc. | Apparatus and method for therapeutic delivery of medication |
US20060104969A1 (en) * | 2004-08-16 | 2006-05-18 | Massachusetts Institute Of Technology | Compositions and methods for enhancing structural and functional nervous system reorganization and recovery |
EP1937263A2 (en) * | 2005-10-04 | 2008-07-02 | Medivation, Inc. | Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease |
JP2009531304A (ja) * | 2006-02-28 | 2009-09-03 | エラン ファーマシューティカルズ,インコーポレイテッド | α−4阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法 |
EP4276469A3 (en) | 2006-02-28 | 2024-01-17 | Biogen MA Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
EA016626B1 (ru) | 2006-03-03 | 2012-06-29 | Элан Фамэсьютикэлс, Инк. | Способ лечения натализумабом воспалительного и/или аутоиммунного заболевания (варианты) |
DK2034830T3 (da) * | 2006-05-25 | 2014-10-27 | Biogen Idec Inc | Anti-vla-1-antistof til behandling af slagtilfælde |
WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
WO2011020874A1 (en) | 2009-08-20 | 2011-02-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
IN2012DN06139A (ja) | 2010-01-11 | 2015-09-18 | Biogen Idec Inc | |
US11287423B2 (en) | 2010-01-11 | 2022-03-29 | Biogen Ma Inc. | Assay for JC virus antibodies |
US9150618B2 (en) | 2010-10-14 | 2015-10-06 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
AU2012277185A1 (en) * | 2011-06-30 | 2014-02-13 | Gene Techno Science Co., Ltd. | Soluble integrin alpha4 mutant |
WO2013091670A1 (en) * | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
US10119976B2 (en) | 2013-05-28 | 2018-11-06 | Biogen Ma Inc. | Method of assessing risk of PML |
US10624948B2 (en) | 2013-06-26 | 2020-04-21 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
WO2016149248A1 (en) * | 2015-03-15 | 2016-09-22 | Emory University | N-methyl-d-aspartate receptor (nmdar) potentiators, pharmaceutical compositions, and uses related thereto |
KR102641718B1 (ko) | 2018-10-30 | 2024-02-29 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체 |
AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
AU2019373240B2 (en) | 2018-10-30 | 2023-04-20 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
CN112969504B (zh) | 2018-10-30 | 2024-04-09 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
WO2021030438A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
IL47468A (en) | 1975-06-12 | 1979-05-31 | Rehovot Res Prod | Process for the cross-linking of proteins using water soluble cross-linking agents |
NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
ATE114723T1 (de) | 1987-03-02 | 1994-12-15 | Enzon Lab Inc | Organismus als träger für ''single chain antibody domain (scad)''. |
US5011691A (en) | 1988-08-15 | 1991-04-30 | Stryker Corporation | Osteogenic devices |
US5266683A (en) | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
US5284756A (en) | 1988-10-11 | 1994-02-08 | Lynn Grinna | Heterodimeric osteogenic factor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5260210A (en) * | 1989-09-27 | 1993-11-09 | Rubin Lee L | Blood-brain barrier model |
US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5260277A (en) | 1990-09-10 | 1993-11-09 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
WO1992008464A1 (en) | 1990-11-15 | 1992-05-29 | Tanabe Seiyaku Co. Ltd. | Substituted urea and related cell adhesion modulation compounds |
US5219990A (en) | 1991-01-28 | 1993-06-15 | Biogen, Inc. | Papillomavirus e2 trans-activation repressors |
EP0612348B1 (en) | 1991-11-04 | 2003-04-23 | Genetics Institute, LLC | Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
WO1993008823A1 (en) | 1991-11-06 | 1993-05-13 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
US5932214A (en) | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
EP0677060A1 (en) | 1993-01-08 | 1995-10-18 | Tanabe Seiyaku Co., Ltd. | Peptide inhibitors of cell adhesion |
DE69419721T2 (de) | 1993-01-12 | 2000-04-27 | Biogen Inc | Rekombinante anti-vla4 antikörpermoleküle |
DE69407758T3 (de) | 1993-02-09 | 2007-05-24 | Biogen Idec Ma Inc., Cambridge | Antikörper zur behandlung von insulinabhängigem diabetes |
WO1995015973A1 (en) | 1993-12-06 | 1995-06-15 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
EP0804237B8 (en) * | 1994-01-25 | 2006-11-08 | Elan Pharmaceuticals, Inc. | Humanized antibodies against leukocyte adhesion molecule vla-4 |
US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
US5510332A (en) | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
WO1996001644A1 (en) | 1994-07-11 | 1996-01-25 | Athena Neurosciences, Inc. | Inhibitors of leukocyte adhesion |
US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
GB9524630D0 (en) | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
WO1996040781A1 (en) | 1995-06-07 | 1996-12-19 | Tanabe Seiyaku Co., Ltd. | CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION |
EP0842195A1 (en) | 1995-07-06 | 1998-05-20 | Zeneca Limited | Peptide inhibitors of fibronectine |
US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
JP2002512625A (ja) | 1997-05-29 | 2002-04-23 | メルク エンド カンパニー インコーポレーテッド | 細胞接着阻害薬としての複素環アミド化合物 |
KR20010022413A (ko) * | 1997-07-31 | 2001-03-15 | 진 엠. 듀발 | Vla-4에 의해 매개되는 백혈구 부착을 억제하는 벤질화합물 |
US6153653A (en) * | 1997-11-26 | 2000-11-28 | Protarga, Inc. | Choline compositions and uses thereof |
JP2002538167A (ja) * | 1999-03-03 | 2002-11-12 | バイオジェン インコーポレイテッド | 脂質の代謝および貯蔵を調節する方法 |
US9501219B2 (en) | 2012-01-25 | 2016-11-22 | Oracle International Corporation | 2D line data cursor |
US9713013B2 (en) | 2013-03-15 | 2017-07-18 | Elwha Llc | Protocols for providing wireless communications connectivity maps |
US9400266B2 (en) | 2013-03-14 | 2016-07-26 | Rosemount Analytical Inc. | Gas chromatograph with improved operation |
US9104862B2 (en) | 2013-04-01 | 2015-08-11 | Uniquesoft, Llc | Secure computing device using new software versions |
-
2000
- 2000-12-14 CA CA2394431A patent/CA2394431C/en not_active Expired - Lifetime
- 2000-12-14 EP EP10185454A patent/EP2332578A1/en not_active Withdrawn
- 2000-12-14 DK DK00984395T patent/DK1242118T3/da active
- 2000-12-14 DK DK09012818.2T patent/DK2140881T3/da active
- 2000-12-14 ES ES09012818T patent/ES2415708T3/es not_active Expired - Lifetime
- 2000-12-14 NZ NZ519447A patent/NZ519447A/en not_active IP Right Cessation
- 2000-12-14 EP EP09012818.2A patent/EP2140881B1/en not_active Expired - Lifetime
- 2000-12-14 WO PCT/US2000/033942 patent/WO2001043774A1/en active IP Right Grant
- 2000-12-14 ES ES00984395T patent/ES2335643T3/es not_active Expired - Lifetime
- 2000-12-14 AT AT00984395T patent/ATE447969T1/de not_active IP Right Cessation
- 2000-12-14 JP JP2001544910A patent/JP2003517023A/ja active Pending
- 2000-12-14 AU AU21020/01A patent/AU783110B2/en not_active Expired
- 2000-12-14 DE DE60043308T patent/DE60043308D1/de not_active Expired - Lifetime
- 2000-12-14 EP EP00984395A patent/EP1242118B1/en not_active Expired - Lifetime
-
2002
- 2002-06-13 US US10/170,841 patent/US20020197233A1/en not_active Abandoned
-
2011
- 2011-10-21 JP JP2011232255A patent/JP5519612B2/ja not_active Expired - Lifetime
-
2012
- 2012-06-12 JP JP2012133117A patent/JP2012167128A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
NZ519447A (en) | 2004-03-26 |
EP2332578A1 (en) | 2011-06-15 |
ES2335643T3 (es) | 2010-03-31 |
JP2012167128A (ja) | 2012-09-06 |
CA2394431A1 (en) | 2001-06-21 |
EP1242118A1 (en) | 2002-09-25 |
JP5519612B2 (ja) | 2014-06-11 |
AU783110B2 (en) | 2005-09-22 |
ATE447969T1 (de) | 2009-11-15 |
CA2394431C (en) | 2015-06-30 |
JP2012017345A (ja) | 2012-01-26 |
EP1242118B1 (en) | 2009-11-11 |
DE60043308D1 (de) | 2009-12-24 |
US20020197233A1 (en) | 2002-12-26 |
DK2140881T3 (da) | 2013-05-06 |
AU2102001A (en) | 2001-06-25 |
WO2001043774A1 (en) | 2001-06-21 |
EP2140881B1 (en) | 2013-04-17 |
EP2140881A1 (en) | 2010-01-06 |
ES2415708T3 (es) | 2013-07-26 |
JP2003517023A (ja) | 2003-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1242118T3 (da) | Fremgangsmåder til behandling af iskæmisk eller hæmorrhagisk beskadigelse af centralnervesystemet under anvendelse af anti-alfa4-integrin-antagonister | |
BRPI0415361A (pt) | antagonistas do receptor muscarìnico de acetilcolina | |
DE69532162D1 (de) | Cannabinoid-rezeptor-antagonisten | |
IT1304150B1 (it) | Derivati di ammine cicliche che sono antagonisti di recettori ccr-3,composizioni farmaceutiche che li contengono, metodi per il loro | |
DE69929235D1 (de) | Spiro-indole als y5-rezeptor antagonisten | |
IT1313625B1 (it) | Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina. | |
DK1244447T3 (da) | Nye fremgangsmåder og sammensætninger indeholdende opioider og deres antagonister | |
TR200101398T2 (tr) | Pirolidin türevleri-CCR-3 reseptörü antagonistleri. | |
DE60021282D1 (de) | Carbamat-derivate als muscarin-rezeptor antonisten | |
ATE505190T1 (de) | Azabicycloalkane als ccr5-modulatoren | |
FI952064A (fi) | Takykiniinireseptoriantagonisteja, joilla ei ole peptidyylirakennetta | |
BR9709072A (pt) | Derivados indol úteis como antagonistas dos receptores endotelina | |
ATE295839T1 (de) | N-(3-ethinylphenylamino)-6,7-bis(2-methoxyethox )-4-chinazolinamin-mesylat-anhydrat und -monohydrat | |
UY28646A1 (es) | Nuevos antagonistas del receptor muscarinico m3 de acetilcolina | |
BR9809071A (pt) | Agentes farmacológicos | |
EE200100146A (et) | Alfa-4 subühikut kandva integriini ja alfa-4 subühikut kandva integriini ligandi vahelise interaktsiooni antagonisti kasutamine | |
DE60032905D1 (de) | Selektive iglur5 rezeptorantagonisten zur behandlung der migräne | |
IS5295A (is) | Azetidínýlprópýlpíperidín afleiður, milliefni og notkun sem mótlyf gegn kínínhröðun | |
UY28645A1 (es) | Nuevos antagonistas del receptor muscarinico m3 de acetilcolina | |
BR9909486A (pt) | Compostos calcilìticos | |
DE60020595D1 (de) | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren | |
NO995711D0 (no) | Kinolin-4-karboksamid-derivater som NK-2 og NK-3-reseptorantagonister | |
NO20014486D0 (no) | Nye LHRH antagonister med forbedrede opplöselighetsegenskaper | |
DK1140026T3 (da) | Serotoninreceptorantagonist indkapslet i biologisk nedbrydelig polymer og fremgangsmåde til fremstilling af samme | |
DE10003866B8 (de) | Zusammensetzungen enthaltend stabilisierte Metallocen-Polyolefine, sowie Verfahren zum Stabilisieren von Metallocen-Polyolefinen |